Exhibit 10.49


 


THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.


 





 


SUPPLY
AGREEMENT


 


BY AND
BETWEEN


 


ANTHROGENESIS
CORPORATION


 


AND


 


ALLIQUA,
INC.


 


NOVEMBER
14, 2013


 




    	 



    	 



    

 


TABLE OF CONTENTS


 


	 	 	PAGE
	 	 	 
	ARTICLE 1  DEFINITIONS	1
	 	 
	ARTICLE 2  SUPPLY OF MANUFACTURED PRODUCTS	2
	 	 
	2.1	Sale and Purchase of Manufactured Products	2
	2.2	Forecasts; Firm Orders	3
	2.3	Shipment and Delivery	3
	2.4	Alliqua Right to Manufacture	4
	2.5	Manufacture and Supply of ECMs	4
	 	 	 
	ARTICLE 3  REGULATORY AND QUALITY MATTERS	4
	 	 
	3.1	Regulatory Responsibility	4
	3.2	Change Control	5
	3.3	Records	5
	3.4	Testing	5
	3.5	Regulatory Inquiries	5
	3.6	Notice of Regulatory Inspections	6
	3.7	Quality Agreement	6
	3.8	Quality Audits	6
	3.9	Intentionally Omitted	7
	3.10	Cooperation	7
	3.11	Recalls	7
	3.12	Complaints	8
	3.13	Warning Letters	8
	3.14	Inquiries from Health Care Professionals	8
	3.15	Debarment	8
	3.16	Additional Covenants of Alliqua	8
	 	 	 
	ARTICLE 4  PRICE AND PAYMENT TERMS	9
	 	 
	4.1	Purchase Price	9
	4.2	Taxes	9
	4.3	Freight and Insurance	9
	4.4	Payments	9
	4.5	Interest Charges	10
	4.6	Pricing	10
	 	 	 
	ARTICLE 5  INSPECTION OF MANUFACTURED PRODUCTS	10
	 	 
	5.1	Inspection by Alliqua	10
	5.2	Disputes Over Manufactured Products	10
	5.3	Replacement of Manufactured Products That Are Not Acceptable Manufactured Products	10


 




    	-i-



    	 



    

 


	5.4	Exclusive Remedy	11
	 	 	 
	ARTICLE 6  REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS	11
	 	 
	6.1	Mutual Representations and Warranties	11
	6.2	Additional CCT Representations and Warranties	11
	6.3	Alliqua Compliance with Applicable Law	12
	 	 	 
	ARTICLE 7  INDEMNIFICATION AND INSURANCE	12
	 	 
	7.1	CCT Indemnification	12
	7.2	Alliqua Indemnification	12
	7.3	Indemnification Procedures	13
	7.4	Limitation of Liability	13
	7.5	Insurance	13
	 	 	 
	ARTICLE 8  CONFIDENTIAL INFORMATION	14
	 	 
	8.1	Confidentiality	14
	8.2	Authorized Disclosure	14
	8.3	Return of Confidential Information	15
	8.4	Publicity; Terms of the Agreement; Confidential Treatment	15
	8.5	Technical Publication	16
	8.6	Equitable Relief	16
	 	 	 
	ARTICLE 9  TERM AND TERMINATION	16
	 	 
	9.1	Term	16
	9.2	Termination	16
	9.3	Effects of Termination	18
	 	 	 
	ARTICLE 10  GENERAL PROVISIONS	18
	 	 	 
	10.1	Entire Agreement; Amendment	18
	10.2	Force Majeure	18
	10.3	Notices	19
	10.4	No Strict Construction; Headings	20
	10.5	Assignment	20
	10.6	Performance by Affiliates	20
	10.7	Further Actions	20
	10.8	Severability	20
	10.9	No Waiver	21
	10.10	Independent Contractors	21
	10.11	Governing Law	21
	10.12	Counterparts	21


 




    	-ii-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


SUPPLY AGREEMENT


 


THIS SUPPLY AGREEMENT
(this “Agreement”) dated as of November 14, 2013 (the “Effective Date”), by and between Anthrogenesis
Corporation, a Delaware corporation doing business as Celgene Cellular Therapeutics (“CCT”), and Alliqua, Inc.,
a Florida corporation (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or
collectively be referred to as the “Parties”.


PREAMBLE


 


A.           CCT
and Alliqua are entering into a License, Marketing and Development Agreement (the “License Agreement”) concurrently
herewith, under which CCT will grant certain rights to Alliqua to market and sell the Licensed Products; and


 


B.           In
connection with the License Agreement, CCT wishes to supply to Alliqua, and Alliqua wishes to purchase from CCT, Alliqua’s
entire requirements of Manufactured Product for distribution and sale in the Territory;


 


NOW, THEREFORE,
in consideration of the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, CCT and Alliqua agree as follows:





 


ARTICLE
1

DEFINITIONS


 


All capitalized terms
used but not defined herein shall have the meaning ascribed to such term in the License Agreement. In addition to the terms defined
in the License Agreement and elsewhere in this Agreement, the following terms have the meanings indicated:


 


“Acceptable
Manufactured Products” has the meaning set forth in Section 5.1.


 


“Act”
means the Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, guidelines and requirements of the FDA
as may be in effect from time to time.


 


“Alliqua Indemnified Parties”
has the meaning set forth in Section 7.1.


 


“Calendar
Year” means each successive period of twelve (12) calendar months commencing on January 1.


 


“CCT Indemnified
Parties” has the meaning set forth in Section 7.2.


 


“CCT Recall
Event” has the meaning set forth in Section 3.11.


 


“CFR”
has the meaning set forth in Section 3.1.


 




    	 



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


“cGTPs”
means current Good Tissue Practices as described in Part 1271 of Title 21 of the U.S. Code of Federal Regulations.


 


“FDA”
means the United States Food and Drug Administration or any successor agency performing a similar function.


 


“Firm Order”
means a written irrevocable firm purchase order for Manufactured Products, which order shall include a delivery schedule specifying
the required delivery date and quantity for each Manufactured Product stock keeping unit ordered and the location to which shipment
of Manufactured Products is to be delivered.


 


“Forecast”
has the meaning set forth in Schedule 2.2, subsection (a)(ii).


 


“Long Range
Forecast” has the meaning set forth in Schedule 2.2, subsection (a)(i).


 


“Losses”
has the meaning set forth in Section 7.1.


 


“Manufactured
Product” means Biovance.


 


“Permitted
Subcontractor” has the meaning set forth in Section 2.1(d).


 


“Product Samples”
has the meaning set forth in Section 3.4.


 


“Purchase
Price” has the meaning set forth in Section 4.1.


 


“Quality Agreement”
has the meaning set forth in Section 3.7.


 


“Required
Manufacturing Changes” has the meaning set forth in Section 3.2.


 


“Specifications”
means the applicable specifications for manufacturing, storage, testing, and bulk packaging of a Manufactured Product as set forth
on Schedule A hereto, as it may be amended from time to time.


 


“Term”
has the meaning set forth in Section 9.1.


 


“Third Party
Claims” has the meaning set forth in Section 7.1.


 


ARTICLE
2

SUPPLY OF MANUFACTURED PRODUCTS


 


2.1          Sale
and Purchase of Manufactured Products.


 


(a)          Subject
to the terms and on the conditions set forth in this Agreement, commencing no earlier than April 1, 2014, CCT shall supply and
sell to Alliqua, and Alliqua shall purchase from CCT, Alliqua’s entire requirements of bulk Manufactured Products for exploitation
in the Territory under the License Agreement. The bulk form and bulk packaging of Manufactured Products shall be in accordance
with the Specifications.


 




    	-2-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


(b)          CCT
shall manufacture, store at its facility, and test all bulk Manufactured Products or cause the same to be manufactured, stored
at the manufacturing facility, and tested, in conformity with the applicable Specifications for such Manufactured Product and in
compliance with all applicable Law, including cGTPs, and the terms and conditions of this Agreement and the Quality Agreement.


 


(c)          Alliqua
shall be solely responsible for all labels, labeling, tracking letters, and packaging of finished Manufactured Products, including
package inserts and outserts for each Manufactured Product in the Territory.


 


(d)          Subject
to any legal requirements under applicable Law, CCT may, at its sole option, engage or use subcontractors and suppliers that it
reasonably believes are qualified to perform some or all of CCT’s obligations under this Agreement (each, a “Permitted
Subcontractor”).


 


(e)          Without
limiting the foregoing, all Permitted Subcontractors shall be subject to the applicable terms and conditions of this Agreement
and the Quality Agreement and no agreement with any Permitted Subcontractor shall release CCT from any of its obligations under
this Agreement or the Quality Agreement. CCT shall remain responsible for any services performed by such Permitted Subcontractor
to the same extent as if it had performed the obligations itself.


 


(f)          For
the purposes of clarity, nothing in this Agreement shall provide a right of reference to support any filing by Alliqua or an Alliqua
Affiliate with the FDA for any product other than the Manufactured Products or to support any similar filing with another Governmental
Authority in or out of the Territory.


 


2.2          Forecasts;
Firm Orders. The Parties shall comply with the provisions of Schedule 2.2 to this
Agreement with respect to the matters set forth therein.


 


2.3          Shipment
and Delivery.


 


(a)          CCT
shall deliver to Alliqua the Manufactured Products ordered pursuant to a Firm Order by the required delivery dates therefor EXW
(Incoterms 2010) CCT’s designated facility in the United States. For purposes of clarity, Alliqua bears all risk and costs
from the time Alliqua or its carrier picks up the Manufactured Products at CCT’s designated facility in the United States
and CCT has no obligation to load the Manufactured Products or clear them for export.


 


(b)          CCT
shall package Manufactured Products in bulk for shipment in accordance with practices that are customary and reasonable in the
industry with respect to similar products and comply with applicable Law, unless otherwise specified in writing by Alliqua at least
ten (10) Business Days prior to such shipment, in which event CCT shall package Manufactured Products in bulk for shipment in accordance
with such instructions and any commercially reasonable, documented actual external costs incurred by CCT (without markup) on account
of the bulk packaging changes requested by Alliqua shall be promptly reimbursed by Alliqua.


 




    	-3-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


(c)          Prior
to shipment, CCT shall perform release testing for the Manufactured Product pursuant to the Specifications, cGTPs and the Quality
Agreement.


 


2.4          Alliqua
Right to Manufacture.


 


(a)          If
CCT terminates this Agreement pursuant to Section 9.2(a), or Alliqua terminates this Agreement pursuant to Section 9.2(b), (c)
or (d), then, for so long as Alliqua has the right to Commercialize the Manufactured Products in the Territory under the License
Agreement, Alliqua or any person or entity designated by Alliqua (including an Affiliate of Alliqua) may, following notice to CCT,
manufacture, store at is facility, and test Alliqua’s requirements of the Manufactured Products for Commercialization in
the Field in the Territory in accordance with the License Agreement.


 


(b)          If
Alliqua elects to manufacture, store, and test Alliqua’s requirements of the Manufactured Products in accordance with Section
2.4(a), CCT shall cooperate with and assist Alliqua or any person or entity designated by Alliqua (including an Affiliate of Alliqua)
in transferring the processes for manufacturing, storing and testing the Manufactured Product to Alliqua or any person or entity
designated by Alliqua (including an Affiliate of Alliqua).


 


2.5          Manufacture
and Supply of ECMs. Prior to the anticipated date of Regulatory Clearance and/or Approval of the first of CCT’s extracellular
matrix derived from the human placenta (“ECM”) products, the Parties shall enter into a supply agreement with
respect to such ECM product that is on substantially the same terms as this Agreement, except that the purchase price shall be
as set forth in Schedule 2.5 to this Agreement.


 


ARTICLE
3

REGULATORY AND QUALITY MATTERS


 


3.1          Regulatory
Responsibility. Subject to the terms of this Agreement and the License Agreement, all matters in the Territory regarding obtaining
and supporting Regulatory Clearance and/or Approval of the Manufactured Products, and manufacturing and testing of the Manufactured
Products in compliance with the applicable Specifications for the Manufactured Product and applicable Law (including cGTPs), shall
be the responsibility of, and shall remain under the control of CCT. Except as set forth in Section 3.2 below, any costs or expenses
required to comply with CCT’s obligations under this Section 3.1 shall be borne by [****]. Each Party shall be registered
with the FDA’s Center for Biologics Evaluation and Research pursuant to 21 Code of Federal Regulations (“CFR”)
Part 1271, as and when their activities with respect to Manufactured Products require such registration. Each Party shall promptly
(within three (3) Business Days) provide the other Party with copies of all communications received from any Regulatory Authority
concerning the Manufactured Products which directly or indirectly affect or relate to the manufacturing, storage, testing, packaging
or labeling thereof, and any filings that directly or indirectly affect or relate to the manufacturing, storage, testing, packaging
or labeling of the Manufactured Products to be made to any such agency for prior review and comment at least five (5) Business
Days prior to such submission. Each Party shall provide notice to the other Party of meetings with any Regulatory Authority, whether
via electronic means, in person, or otherwise, which affect or relate to the manufacturing, storing, testing, packaging or labeling
of the Manufactured Products. CCT will require each Permitted Subcontractor to keep CCT and Alliqua fully and promptly advised
of any inspections, inspectional observations and other communications and interactions between such Permitted Subcontractor and
any Regulatory Authority which may directly or indirectly affect or relate to the manufacturing, storage, testing, packaging or
labeling of any Manufactured Products. In the event of any inconsistency between the provisions of this Section 3.1 and the provisions
of the License Agreement, the provisions of the License Agreement shall control.


 




    	-4-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


3.2           Change
Control. CCT and Alliqua shall cooperate in timely making any and all changes to the Specifications or manufacturing processes
that are required by applicable Law (collectively, “Required Manufacturing Changes”). The commercially reasonable,
documented costs attributable to the Required Manufacturing Change, including the cost of a reasonable quantity (in light of the
Forecasts submitted by Alliqua) of raw materials, work-in-process, Manufactured Products and bulk packaging materials rendered
obsolete as a result of any such Required Manufacturing Changes, shall be borne [****].


 


3.3           Records.
CCT shall, and shall cause its Affiliates and each Permitted Subcontractor to, keep appropriate accounts, notes, data and records
of the work performed under this Agreement in accordance with applicable Law, including cGTPs, and the terms and conditions of
this Agreement and the Quality Agreement. CCT shall provide Alliqua with a copy of a certificate of analysis with each batch of
Manufactured Products delivered to Alliqua, as set forth in the Quality Agreement.


 


3.4           Testing.
CCT shall be solely responsible for (a) taking and maintaining quality control samples of all Manufactured Products delivered to
Alliqua (collectively, the “Product Samples”), and (b) testing Product Samples, in each case, in accordance
with the Quality Agreement. CCT shall promptly provide Alliqua data resulting from testing related to the Product Samples for distribution
in the Territory as such information becomes available, including any discovery of any negative or adverse trending in testing
data.


 


3.5           Regulatory
Inquiries. Without limiting any provision of the License Agreement, upon being contacted (and, in the case of CCT, upon any
Permitted Subcontractor being contacted) by any Regulatory Authority for any regulatory purpose pertaining to this Agreement or
to the Manufactured Products, including notice of the initiation of any inquiries, notices or inspection activity by any such agency,
a Party shall immediately notify the other Party and provide the other Party with (a) a reasonable description of any such inquiries
and related documentation, (b) an opportunity to advise and comment with respect thereto and (c) if appropriate, an opportunity
to participate with respect thereto to the extent such matters relate to the Manufactured Products in the Territory.


 




    	-5-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


3.6          Notice
of Regulatory Inspections. Each Party shall (a) advise the other Party of any requests by any Regulatory Authority (including,
in the case of CCT, any such requests made to a Permitted Subcontractor) for any inspections with respect to the manufacturing,
storing, testing, packaging and/or labeling of Manufactured Products, (b) provide the other Party with copies of any correspondence
related thereto, and, to the extent it (or, in the case of CCT, by a Permitted Subcontractor) becomes aware of the results, observations
or outcome of any inspections or audits of the facilities or operations involved in the manufacture, storage, testing, packaging
and/or labeling of the Manufactured Products conducted by any Regulatory Authority, including providing the other Party an opportunity
to advise and comment with respect to any correspondence to be provided by such Party (or, in the case of CCT, by a Permitted Subcontractor)
to the applicable agency, and (c) notify the other Party of any such information as it relates to the Manufactured Products in
the Territory within three (3) Business Days of obtaining the information.


 


3.7          Quality
Agreement. Within sixty (60) Business Days after the Effective Date, CCT and Alliqua shall negotiate in good faith the terms
of, and enter into, a reasonable and customary quality agreement (the “Quality Agreement”). The Quality Agreement
shall include provisions with respect to, among other things, release testing, change control procedures with respect to the Specifications
and the manufacturing processes for the Manufactured Products, stability testing, recalls of any Manufactured Products, and record
retention requirements with respect to recalls. In the event of any conflict between the terms of the Quality Agreement and the
terms of this Agreement, the terms of the Quality Agreement shall govern.


 


3.8          Quality
Audits. 


 


(a)          Upon
reasonable advance notice and during reasonable business hours, Alliqua shall have the right to inspect and audit those portions
of CCT’s and its Affiliates’ and its Permitted Subcontractors’ facilities in which the Manufactured Products
are manufactured, stored or tested, to ascertain compliance with cGTPs, applicable Law, and the terms and conditions of this Agreement
and the Quality Agreement; provided, however, that (i) Alliqua’s representatives shall follow all security and facility access
procedures as reasonably required by CCT or its Affiliate or Permitted Subcontractor, as applicable, and (ii) Alliqua may not exercise
its right under this Section 3.8(a) more than once in any twelve (12)-month period (unless such inspection and audit reveals a
material compliance issue, in which event Alliqua shall have the right to conduct a follow-up inspection and audit to verify that
such issue has been remedied). CCT shall use commercially reasonable efforts to promptly resolve, and to cause its Affiliates and
its Permitted Subcontractors to promptly resolve, any quality issues raised by any inspections and audits of their respective facilities.


 


(b)          Upon
reasonable advance notice and during reasonable business hours, CCT shall have the right to inspect and audit (i) those portions
of Alliqua’s facilities in which the Manufactured Products are stored, handled or labeled and (ii) if Alliqua elects to manufacture,
store, and test Alliqua’s requirements of the Manufactured Products or designate another person or entity to manufacture,
store, and test Alliqua’s requirements of the Manufactured Products, in accordance with Section 2.4(a), those portions of
Alliqua’s facilities or those of its designated Person, as the case may be, in which the Manufactured Products are manufactured,
stored, handled or labeled, in each case, to ascertain compliance with cGTPs, applicable Law, and the terms and conditions of this
Agreement and the Quality Agreement; provided, however, that (i) CCT’s representatives shall follow all security and facility
access procedures as reasonably required by Alliqua, as applicable, and (ii) CCT may not exercise its right under this Section
3.8(a) more than once in any twelve (12)-month period (unless such inspection and audit reveals a material compliance issue, in
which event CCT shall have the right to conduct a follow-up inspection and audit to verify that such issue has been remedied).
Alliqua shall use commercially reasonable efforts to promptly resolve any quality issues raised by any inspections and audits of
its facilities.


 




    	-6-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


(c)          Except
as otherwise set forth in this Agreement, each Party shall, at its sole cost and expense, maintain in full force and effect all
necessary licenses, approvals, permits and other authorizations required by applicable Law to carry out its duties and obligations
under this Agreement and the Quality Agreement.


 


3.9          Intentionally
Omitted.


 


3.10        Cooperation.
The Parties will cooperate in good faith in responding to any Regulatory Authority inquiry or in making any report to the Regulatory
Authority with respect to Manufactured Products. Notwithstanding anything to the contrary in this Agreement (and without limiting
CCT’s obligation under the License Agreement to obtain, support and maintain Regulatory Clearances and/or Approvals), CCT
will have final authority for regulatory decisions and responsibility for all communications with any Regulatory Authority with
respect to obtaining or maintaining Regulatory Approval of the Manufactured Products.


 


3.11        Recalls.
CCT and Alliqua will each notify the other Party promptly if it becomes aware that a Manufactured Product is the subject of a recall
or market withdrawal that is mandated by a Regulatory Authority, and the Parties will reasonably cooperate in the handling and
disposition of such recall or market withdrawal; provided, however, in the event of a disagreement as to any matters related to
any such recall or market withdrawal, other than the determination of who will bear the costs as set forth in the immediately following
sentences, CCT will have the final authority with respect to any product recall or withdrawal relating to Manufactured Products,
including any recall or market withdrawal that is not mandated by a Regulatory Authority. [****] will bear the cost of all recalls
or market withdrawals of Manufactured Products purchased by Alliqua pursuant to this Agreement where such recall or market withdrawal
is the direct result of CCT’s or a Permitted Subcontractor’s [****] Recall Event”). [****] will bear the
cost of all recalls or market withdrawals of Manufactured Products purchased by Alliqua pursuant to this Agreement where such recall
or market withdrawal is the direct result of Alliqua’s [****] Recall Event”). If a recall or market withdrawal
[****], then the costs of such recall or market withdrawal will be [****] will bear the cost of all recalls or market withdrawals
of Manufactured Products purchased by Alliqua pursuant to this Agreement where the recall or market withdrawal is [****]. Alliqua
will maintain records of all sales of Manufactured Product and all customers sufficient to adequately administer a recall or market
withdrawal for the longer of one (1) year after termination or expiration of this Agreement or the period required by applicable
Law. Alliqua will, in all events and regardless of who bears the cost, be responsible for administering the physical aspects of
any recalls or market withdrawals with respect to the Manufactured Products, provided, however, that any reasonable external costs
and expenses incurred by Alliqua relating to the recall or market withdrawal (including, but not limited to reasonable recall destruction
costs) will be allocated between the Parties as set forth above in this Section. Any revenue attributable to Manufactured Products
held or sold by Alliqua (or its designee) that is subject to a recall will be deducted from Net Sales for purposes of the License.
In the event of any recall, if requested by Alliqua, CCT will provide Manufactured Products to Alliqua to replace the recalled
Manufactured Products and, to the extent the recalled Manufactured Products were previously paid for by Alliqua, the cost of such
replacement Manufactured Products shall be allocated between the Parties as set forth above in this Section.


 




    	-7-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


3.12        Complaints.
Alliqua will collect complaint files for the Manufactured Products in accordance with the provisions of the Quality Agreement.
Manufactured Products complaint reports received by Alliqua will be sent to CCT at [****] within twenty-four (24) hours after receipt
of the complaint by Alliqua. Alliqua and CCT will notify each other of any Manufactured Product complaints made by customers that
will or could require a report of an “adverse reaction” to the FDA pursuant to 21 CFR 1271.350, and will thereafter
reasonably cooperate with each other relative to any investigation or inquiry that may be initiated by FDA with respect thereto.
The complaint handling obligations of the Parties will be detailed further within the Quality Agreement and/or the Safety Data
and Exchange Agreement.


 


3.13        Warning
Letters. In the event that either Party (or, in the case of CCT, any Permitted Subcontractor) receives a warning letter from
the FDA or the equivalent from any other Governmental Authority in connection with the Manufactured Product, such Party will notify
the other Party promptly, and in any event within twenty four (24) hours (to the extent legally permitted) after receiving such
warning letter.


 


3.14        Inquiries
from Health Care Professionals. CCT shall provide reasonable assistance to Alliqua in its preparation and filing with appropriate
Regulatory Authorities related to reimbursement and health care insurance filings required for the marketing and distribution of
Manufactured Products in the Territory by Alliqua.


 


3.15        Debarment.
Neither Party shall use any employee or consultant (or, in the case of CCT, any Permitted Subcontractor or employees or consultants
thereof) who has been debarred by any Regulatory Authority, or, to such Party's knowledge, is the subject of debarment proceedings
by a Regulatory Authority. Each Party shall notify the other Party promptly upon becoming aware that any of its employees or consultants
(or, in the case of CCT, any Permitted Subcontractor or employees or consultants thereof) has been debarred or is the subject of
debarment proceedings by any Regulatory Authority.


 


3.16        Additional
Covenants of Alliqua. Alliqua shall:


 


(a)          discharge
its obligations pursuant to this Agreement in accordance with all applicable Laws, including those enforced by the FDA (including
compliance with cGTP);


 


(b)          maintain
the Manufactured Products pending sale to its customers in a facility that is properly equipped to store such Manufactured Products
in accordance with the applicable Manufactured Product labeling; and


 




    	-8-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


(c)          comply
in all respects with Article 3 hereof and the Quality Agreement and the Safety Data and Exchange Agreement.



 


ARTICLE
4

PRICE AND PAYMENT TERMS


 


4.1          Purchase
Price.


 


(a)          For
all Manufactured Products ordered pursuant to Firm Orders by Alliqua at any time, Alliqua shall pay CCT a purchase price (“Purchase
Price”) for each conforming quantity of Manufactured Product delivered hereunder in accordance with the terms set forth
in Schedule 4.1 to this Agreement.


 


(b)          If
at any time during the Term, CCT notifies Alliqua in writing that CCT has incurred an increase in the costs associated with manufacturing
the Manufactured Products, the Parties shall promptly negotiate in good faith an increase in the Purchase Price to account for
such increase in costs; provided, however, that if the Parties fail to reach agreement on any such price increase, the resolution
of such disagreement shall be governed by the provisions of Section 13 of the License Agreement.


 


4.2          Taxes.
The Purchase Price and other amounts payable by Alliqua to CCT pursuant to this Agreement shall not be reduced on account of
any taxes unless required by applicable Law. CCT alone shall be responsible for paying any and all taxes (other than any withholding
taxes required by applicable Law to be paid by Alliqua) levied on account of, or measured in whole or in part by reference to,
any payments it receives from Alliqua.


 


4.3          Freight
and Insurance. In addition to the Purchase Price, for the purposes of clarity, Alliqua shall pay all actual freight and insurance
expenses incurred by Alliqua in connection with the sale and shipment of the Manufactured Products.


 


4.4          Payments.



 


(a)          Upon
each delivery of Manufactured Products, CCT shall promptly submit an invoice to Alliqua. All invoices and payments for Manufactured
Products shall be in United States dollars. Alliqua shall pay each invoice (except for any amounts disputed by Alliqua in good
faith) within thirty (30) days after receipt thereof.


 


(b)          If
an inconsistency between any invoice, purchase order, purchase order release, confirmation, acceptance or similar document and
this Agreement exists, the terms of this Agreement shall control.


 


(c)          Payment
due to CCT shall be paid in United States dollars by wire transfer to an account designated in writing by CCT.


 




    	-9-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


4.5           Interest
Charges. If CCT does not receive payment of any sum due to it on or before the due date, simple interest shall thereafter accrue
on the sum due until the date of payment at the rate of [****] per month or, if less, the maximum rate allowable by applicable
Law.


 


4.6           Pricing.
All resale prices of Manufactured Products shall be reviewed by the JSC and Alliqua shall consider in good faith any comments of
the JSC. For purposes of clarity, Alliqua shall have final discretion with respect to resale prices of the Manufactured Products
during the Term, including resale price increases and decreases and the timing thereof.


 


ARTICLE
5

INSPECTION OF MANUFACTURED PRODUCTS


 


5.1           Inspection
by Alliqua. Alliqua may inspect and analyze the Manufactured Products delivered to Alliqua for purposes of determining whether
the Manufactured Products meet the applicable Specifications at the time of delivery thereof (such Manufactured Product, “Acceptable
Manufactured Products”). Alliqua shall notify CCT in writing within thirty (30) days
after the date of delivery to Alliqua (or within thirty (30) days after discovery that any Manufactured
Product is not Acceptable Manufactured Products for reasons that could not reasonably have been detected by Alliqua’s customary
inspection on delivery) of any Manufactured Product or portion thereof which Alliqua is returning because it is not an Acceptable
Manufactured Product, including documentation of the reasons therefor. If CCT does not receive such notice within such thirty (30)-day
period, the shipped Manufactured Products will be deemed accepted as Acceptable Manufactured Products.


 


5.2           Disputes
Over Manufactured Products. CCT shall have a reasonable opportunity not to exceed thirty (30) days from the date of receipt
of the notice described in Section 5.1 to inspect and/or test such Manufactured Product that Alliqua claims is not an Acceptable
Manufactured Product. If CCT, after good faith consultation with Alliqua, disputes any determination by Alliqua that a Manufactured
Product is not an Acceptable Manufactured Product, then representative samples of such Manufactured Product shall be forwarded
to an independent Third Party laboratory jointly selected by CCT and Alliqua, in their reasonable discretion, for analysis, which
analysis shall be performed in compliance with industry standards and applicable Law. The findings of such Third Party laboratory
regarding whether the Manufactured Product was an Acceptable Manufactured Product shall be binding upon the Parties. The cost of
such analysis by such Third Party laboratory shall be borne by the Party whose analysis was not substantiated by the findings of
such Third Party laboratory.


 


5.3           Replacement
of Manufactured Products That Are Not Acceptable Manufactured Products. CCT shall, at Alliqua’s option, either replace
any Manufactured Product order or portion thereof which is not an Acceptable Manufactured Product as soon as reasonably practicable
at CCT’s cost and expense, including shipping costs, or promptly refund to Alliqua the payments made for such returned Manufactured
Products (including Alliqua’s shipping costs). At the sole option of CCT, said Manufactured Products may be returned to CCT,
at CCT’s expense including shipping costs, or destroyed in an environmentally acceptable manner, in accordance with applicable
Law, at CCT’s expense. CCT will not, however, replace any Manufactured Product which fails or ceases to conform to the Specifications
or which is unsalable, in each case, as a result of improper storage, transport or other mishandling or other event after the Manufactured
Product has been delivered to Alliqua, Alliqua’s designated courier or other Alliqua designee.


 




    	-10-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


5.4          Exclusive
Remedy. The sole and exclusive remedy available to Alliqua in connection with Manufactured Products that are not Acceptable
Manufactured Products shall be replacement of such Manufactured Product by CCT in accordance with Section 5.3 above. Notwithstanding
the immediately preceding sentence, Manufactured Products that are not Acceptable Manufactured Products shall be deemed not to
have been delivered for purposes of Section 9.2(b).


 


 


ARTICLE
6

REPRESENTATIONS AND WARRANTIES; CERTAIN COVENANTS


 


6.1          Mutual
Representations and Warranties. Each Party represents and warrants to the other Party as of the Effective Date as follows:


 


(a)          It
is a corporation duly organized, validly existing and in good standing under the laws of the State of its incorporation, with the
requisite legal authority to own and use its properties and assets and to carry on its business as currently conducted.


 


(b)          It
has the requisite corporate authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise
to carry out its obligations hereunder. The execution and delivery of this Agreement by it and the transactions contemplated hereby
and thereby have been duly authorized by all necessary corporate action on its part and no further consent or action is required
by it, by its Board of Directors or by its stockholders.


 


(c)          This
Agreement has been duly executed by it and is the valid and binding obligation of the Company enforceable against it in accordance
with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies.


 


6.2          Additional
CCT Representations and Warranties.  CCT represents and warrants to Alliqua that at the time each Manufactured Product is delivered
to Alliqua such Manufactured Product: (a) will meet the Specifications therefor; (b) will have been manufactured, stored and handled
at CCT’s facility, and tested in accordance with the applicable Law, Regulatory Clearances and/or Approvals, Specifications
and cGTPs; (c) will have a remaining shelf life no less than [****] of the shelf life set forth in the Regulatory Clearances and/or
Approvals therefor in the Territory; (d) will not be (i) adulterated, or (ii) manufactured, stored or handled at CCT’s facility,
or tested in a manner that violates the Act, or any other applicable Law; and (e) will pass to Alliqua free and clear of any security
interest, lien or other encumbrances.


 




    	-11-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


6.3           Alliqua
Compliance with Applicable Law. Alliqua shall at all times: (a) handle, warehouse, store, label, package, market, sell, distribute
and otherwise dispose of the Manufactured Products in the Territory in compliance with all applicable Law, Regulatory Clearances
and/or Approvals, Specifications and cGTPs; and (b) except for any Regulatory Clearances and/or Approvals that CCT is responsible
for maintaining, maintain all applicable licenses, registrations and permits necessary to take control of, market, sell and distribute
such Manufactured Products in the Territory. Alliqua will not market the Manufactured Product in any manner which is inconsistent
with its labeling or with applicable Law, or otherwise make any false or misleading representations to customers or others regarding
the Manufactured Product.


 


ARTICLE
7

INDEMNIFICATION AND INSURANCE


 


7.1           CCT
Indemnification. Subject to the procedures set forth in Section 7.3, CCT shall indemnify Alliqua, its Affiliates and its and
their respective directors, officers, employees and agents (the “Alliqua Indemnified Parties”), and defend and
save each of them harmless, from and against any and all claims, lawsuits, losses, damages, liabilities, penalties, costs and expenses
(including reasonable attorneys’ fees and disbursements) (collectively, “Losses”) incurred by any of them
in connection with any and all suits, investigations, claims or demands of Third Parties (collectively, “Third Party Claims”)
in connection with, arising from or occurring as a result of: (a) the breach or inaccuracy of any representation or warranty made
by CCT in this Agreement or the Quality Agreement; (b) the breach by CCT of any of its obligations under this Agreement or the
Quality Agreement; or (c) any manufacturing defect of the Manufactured Products manufactured by CCT or on its behalf; in each case
except for those Losses for which Alliqua has an obligation to indemnify any CCT Indemnified Parties pursuant to Section 7.2 of
the License Agreement.


 


7.2           Alliqua
Indemnification. Subject to the procedures set forth in Section 7.3, Alliqua shall indemnify CCT, its Affiliates and its and
their respective directors, officers, employees and agents (the “CCT Indemnified Parties”), and defend and save
each of them harmless, from and against any and all Losses incurred by any of them in connection with any Third Party Claims in
connection with, arising from or occurring as a result of: (a) the breach or inaccuracy of any representation or warranty made
by Alliqua in this Agreement or the Quality Agreement; (b) the use of any and all Promotional Materials; (c) the breach by Alliqua
of any of its obligations under this Agreement or the Quality Agreement; or (d) any Manufactured Products manufactured by Alliqua
or on its behalf by any Person other than CCT, in each case except for those Losses for which CCT has an obligation to indemnify
any Alliqua Indemnified Parties pursuant to Section 7.1 or the License Agreement.


 




    	-12-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


7.3          Indemnification
Procedures. The Party claiming indemnity under this Article 7 (the “Indemnified Party”) shall give written
notice to the Party from whom indemnity is being sought (the “Indemnifying Party”) promptly after learning of
such Claim. The Indemnifying Party shall have the right to assume and conduct the defense of the Claim with counsel of its choice,
and the Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense. The
Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party's expense, in connection
with the defense of the Claim for which indemnity is being sought. Each Party shall not settle or compromise any Claim without
the prior written consent of the other Party, which consent shall not be unreasonably withheld, delayed or conditioned. If the
Parties cannot agree as to the application of the foregoing Sections 7.1 and 7.2, each may conduct separate defenses of the Claim,
and each Party reserves the right to claim indemnity from the other in accordance with this Article 7 upon the resolution of the
underlying Claim.


 


7.4          Limitation
of Liability. NEITHER PARTY SHALL BE LIABLE FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES, INCLUDING
LOST PROFITS, ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT EXCEPT FOR FRAUD OR WILLFUL MISCONDUCT, BREACH OF EITHER
PARTY'S CONFIDENTIALITY OBLIGATIONS, A PARTY'S INDEMNIFICATION OBLIGATIONS, A BREACH OF EACH PARTY'S EXCLUSIVITY OBLIGATIONS OR
A BREACH OF THE LICENSE GRANTS, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED, HOWEVER, THAT ANY DAMAGES
CLAIMED BY OR PAID TO A THIRD PARTY IN A THIRD PARTY ACTION SHALL NOT BE CONSIDERED SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE,
OR INDIRECT DAMAGES FOR PURPOSES OF THIS AGREEMENT.


 


7.5          Insurance.
Each Party shall, at all times during the Term of this Agreement and for five (5) years thereafter, obtain and maintain at its
own expense the following types of insurance, with limits of liability not less than those specified below:


 


(a)          Commercial
general liability insurance against claims for bodily injury and property damage which shall include contractual coverage and product
liability coverage, with limits of not less than $[****] per occurrence and in the aggregate. The other Party, its officers, directors,
representatives and agents shall be named as additional insureds.


 


(b)          Workers
compensation and employers' liability with limits to comply with the statutory requirements of the state(s) in which the Agreement
is to be performed. The policy shall include employers' liability for not less than $[****] per accident.


 


All policies shall be
issued by insurance companies with an A.M. Best's rating of Class A-:V (or its equivalent) or higher status. Each Party shall deliver
certificates of insurance evidencing coverage to the other Party promptly after the execution of this Agreement and annually thereafter.
All policies provided for herein shall expressly provide that such policies shall not be cancelled, terminated or altered without
at least thirty (30) days prior written notice to the insured Party, and each insuring Party shall immediately notify the insured
Party in the event that a policy provided for herein is cancelled, terminated or altered.


 




    	-13-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


ARTICLE
8

CONFIDENTIAL INFORMATION


 


8.1          Confidentiality.
During the Term and for a period of five (5) years thereafter, each Party
shall maintain all Confidential Information of the other Party in trust and confidence and shall not, without the written consent
of the other Party, disclose any Confidential Information of the other Party to any Third Party or use any Confidential Information
of the other Party for any purpose other than as necessary in connection with the exercise of rights or discharge of obligations
under this Agreement. The confidentiality obligations of this Section 8.1 shall not apply to Confidential Information to the extent
that the receiving Party can establish by competent evidence that such Confidential Information: (a) is publicly known prior or
subsequent to disclosure without breach of confidentiality obligations by such Party or its employees, consultants or agents; (b)
was in such Party’s possession at the time of disclosure without any restrictions on further disclosure; (c) is received
by such receiving Party, without any restrictions on further disclosure, from a Third Party who has the lawful right to disclose
it; or (d) is independently developed by employees or agents of the receiving Party who had no access to the disclosing Party’s
Confidential Information.


 


8.2          Authorized
Disclosure. Nothing herein shall preclude a Party from disclosing
the Confidential Information of the other Party to the extent:


 


(a)          such
disclosure is reasonably necessary (i) for the filing or prosecuting of Patents as contemplated by the License Agreement; (ii)
to comply with the requirement of Regulatory Authorities with respect to obtaining and maintaining Regulatory Clearance and/or
Approval (or any pricing and reimbursement approvals) of any Manufactured Product; or (iii) for prosecuting or defending litigations
as contemplated by the License Agreement;


 


(b)          such
disclosure is reasonably necessary to its employees, agents, consultants or contractors on a need-to-know basis for the sole purpose
of performing its obligations or exercising its rights under this Agreement; provided that in each case, the disclosees are bound
by written obligations of confidentiality and non-use consistent with those contained in this Agreement;


 


(c)          such
disclosure is reasonably necessary to any bona fide potential or actual investor, acquiror, merger partner, or other financial
or commercial partner for the sole purpose of evaluating an actual or potential investment, acquisition or other business relationship;
provided that in each case, the disclosees are bound by written obligations of confidentiality and non-use consistent with those
contained in this Agreement;


 


(d)          such
disclosure is reasonably necessary to comply with applicable Laws, including regulations promulgated by applicable security exchanges,
a valid order of a court of competent jurisdiction, administrative subpoena or order.


 


Notwithstanding the foregoing,
in the event a Party is required to make a disclosure of the other Party’s Confidential Information pursuant to any of Sections
8.2(a) through 8.2(d), such Party shall promptly notify the other Party of such required disclosure and shall use reasonable efforts
to obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the required disclosure.


 




    	-14-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


8.3          Return
of Confidential Information. Promptly after the termination or expiration of this Agreement for any reason, each Party shall
return to the other Party all tangible manifestations of such other Party’s Confidential Information at that time in the
possession of the receiving Party.


 


8.4          Publicity;
Terms of the Agreement; Confidential Treatment.


 


(a)          The
Parties agree that the terms of this Agreement (including without limitation any exhibits and schedules hereto) shall be considered
Confidential Information of each Party, subject to the special authorized disclosure provisions set forth in Section 8.2 and this
Section 8.4.


 


(b)          If
either Party desires to make a public announcement concerning the material terms of this Agreement, such Party shall give reasonable
prior advance notice of the proposed text of such announcement to the other Party for its prior review and approval (except as
otherwise provided herein), such approval not to be unreasonably withheld, conditioned or delayed. A Party commenting on such a
proposed press release shall provide its comments, if any, within three (3) Business Days after receiving the press release for
review. In addition, to the extent required by applicable Laws, including regulations promulgated by applicable security exchanges,
each Party shall have the right to make a press release announcing the achievement of each milestone under this Agreement as it
is achieved, and the achievements of Regulatory Clearances and/or Approvals in the Territory as they occur, subject to the other
Party’s consent as to form and substance of such announcement, which shall not be unreasonably withheld, conditioned or delayed.
In relation to the other Party’s review and approval of such an announcement, such other Party may make specific, reasonable
comments on such proposed press release within the prescribed time for commentary, but shall not withhold its consent to disclosure
of the information that the relevant milestone has been achieved and triggered a payment hereunder. Neither Party shall be required
to seek the permission of the other Party to repeat any information regarding the terms of this Agreement that has already been
publicly disclosed by such Party, or by the other Party, in accordance with this Section 8.4, provided such information remains
accurate as of such time.


 


(c)          In
addition, the Parties acknowledge that either or both Parties may be obligated to file under applicable law and regulation a copy
of this Agreement with the USA Securities and Exchange Commission or similar stock exchange authorities or other governmental authorities.
Each Party shall be entitled to make such a required filing; provided, however, that it requests confidential treatment of the
commercial terms and sensitive technical terms hereof and thereof to the extent such confidential treatment is reasonably available
to such Party. In the event of any such filing, each Party shall provide the other Party with a copy of this Agreement marked to
show provisions for which such Party intends to seek confidential treatment and shall reasonably consider and incorporate the other
Party’s comments thereon to the extent consistent with the legal requirements, with respect to the filing Party, governing
disclosure of material agreements and material information that must be publicly filed.


 




    	-15-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


8.5          Technical
Publication.  Neither Party may publish peer reviewed manuscripts or give other forms of public disclosure such as abstracts
and media presentations (such disclosure collectively, for purposes of this Section 8.5, “publication”), of
results of studies carried out under this Agreement, without the opportunity for prior review by the other Party, except to the
extent required by applicable Laws. A Party seeking publication shall provide the other Party the opportunity to review and comment
on any proposed publication that relates to the Manufactured Product at least thirty (30) days (or at least ten (10) days in the
case of abstracts and media presentations) prior to its intended submission for publication. The other Party shall provide the
Party seeking publication with its comments in writing, if any, within twenty (20) days (or within five (5) days in the case of
abstracts and media presentations) after receipt of such proposed publication. The Party seeking publication shall consider in
good faith any comments thereto provided by the other Party and shall comply with the other Party’s reasonable request to
remove any and all of such other Party’s Confidential Information from the proposed publication. In addition, the Party seeking
publication shall delay the submission for a period up to sixty (60) days in the event that the other Party can demonstrate reasonable
need for such delay in order to accommodate the preparation and filing of a patent application. If the other Party fails to provide
its comments to the Party seeking publication within such twenty (20) day period (or five (5) day period, as the case may be),
such other Party shall be deemed not to have any comments, and the Party seeking publication shall be free to publish in accordance
with this Section 8.5 after the thirty (30) day period (or ten (10) day period, as the case may be) has elapsed. The Party seeking
publication shall provide the other Party a copy of the publication at the time of the submission. Each Party agrees to acknowledge
the contributions of the other Party and its employees in all publications as scientifically appropriate.


 


8.6          Equitable
Relief. Each Party acknowledges that its breach of Article 8 of this Agreement may cause irreparable injury to the other
Party for which monetary damages may not be an adequate remedy. Therefore, each Party shall be entitled to seek injunctive and
other appropriate equitable relief to prevent or curtail any actual or threatened breach of the obligations relating to Confidential
Information set forth in this Article 8 by the other Party. The rights and remedies provided to each Party in this Article 8 are
cumulative and in addition to any other rights and remedies available to such Party at law or in equity.


 


ARTICLE
9

TERM AND TERMINATION


 


9.1          Term.
The term of this Agreement shall commence on the Effective Date and shall continue until this Agreement is terminated pursuant
to this ARTICLE 9 (the “Term”).


 


9.2          Termination.
This Agreement may be terminated as follows:


 


(a)          By
CCT upon six months’ prior written notice to Alliqua.


 


(b)          By
Alliqua upon [****] prior written notice to CCT if, on at least [****] occasions within any twelve (12) month period, CCT fails
to deliver at least [****]% of any Manufactured Products specified in a Firm Order conforming to the provisions of Schedule 2.2,
subsection (c) by the required delivery date specified therein and in conformity with the applicable Specifications.


 




    	-16-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


(c)          By
either Party immediately upon written notice to the other Party if the other Party materially breaches its obligations under this
Agreement and, after receiving written notice identifying such material breach in reasonable detail, fails to cure such material
breach within sixty (60) days from the date of such notice. If the alleged breaching Party disputes in good faith the existence
or materiality of a breach specified in a notice provided by the other Party in accordance with this Section 9.2(c), and such alleged
breaching Party provides the other Party notice of such dispute within the applicable cure period, then the non-breaching Party
shall not have the right to terminate this Agreement under this Section 9.2(c) unless and until an arbitrator, in accordance with
Article 13 of the License Agreement, has determined that the alleged breaching Party has materially breached the Agreement and
such breaching Party fails to cure such breach within the applicable cure period (measured as commencing after the arbitrator’s
decision). It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement
shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.


 


(d)          
To the extent permitted under applicable Laws, if at any time during the Term of this Agreement, an Event of Bankruptcy (as defined
below) relating to either Party (the “Bankrupt Party”) occurs, the other Party (the “Non-Bankrupt Party”)
shall have, in addition to all other legal and equitable rights and remedies available hereunder, the option to terminate this
Agreement upon sixty (60) days written notice to the Bankrupt Party. It is agreed and understood that if the Non-Bankrupt Party
does not elect to terminate this Agreement upon the occurrence of an Event of Bankruptcy, except as may otherwise be agreed with
the trustee or receiver appointed to manage the affairs of the Bankrupt Party, the Non-Bankrupt Party shall continue to make all
payments required of it under this Agreement as if the Event of Bankruptcy had not occurred, and the Bankrupt Party shall not have
the right to terminate any license granted herein. The term “Event of Bankruptcy” means: (a) filing, in any
court or agency pursuant to any statute or regulation of any state or country, (i) a petition in bankruptcy or insolvency, (ii)
for reorganization or (iii) for the appointment of (or for an arrangement for the appointment of) a receiver or trustee of the
Bankrupt Party or of its assets; (b) with respect to the Bankrupt Party, being served with an involuntary petition filed in any
insolvency proceeding, which such petition is not dismissed within sixty (60) days after the filing thereof; (c) proposing or being
a party to any dissolution or liquidation when insolvent; or (d) making an assignment for the benefit of creditors. Without limitation,
the Bankrupt Party’s rights under this Agreement shall include those rights afforded by 11 USAC. § 365(n) of the United
States Bankruptcy Code (the “Bankruptcy Code”) and any successor thereto. If the bankruptcy trustee of a Bankrupt
Party as a debtor or debtor-in-possession rejects this Agreement under 11 USAC. § 365(o) of the Bankruptcy Code, the Non-Bankrupt
Party may elect to retain its rights licensed from the Bankrupt Party hereunder (and any other supplementary agreements hereto)
for the duration of this Agreement and avail itself of all rights and remedies to the full extent contemplated by this Agreement
and 11 USAC. § 365(n) of the Bankruptcy Code, and any other relevant Laws..


 




    	-17-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


(e)          This
Agreement shall automatically terminate upon expiration or termination of the License Agreement.


 


9.3          Effects
of Termination.


 


(a)          Upon
termination of this Agreement for any reason, all submitted Firm Orders for Manufactured Products shall be delivered and paid for
in accordance with Article 2.


 


(b)          Termination
or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit
of a Party prior to such termination or expiration.


 


(c)          Section
3.11, this Section 9.3 and Articles 1, 4, 5, 6, 7, 8 and 10 shall survive expiration or termination of this Agreement for any reason;
Schedule 2.2, subsection (h) and Section 2.4 shall survive a termination of this Agreement pursuant to Section 9.2(a) or (b); and,
with respect to Firm Orders submitted and/or filled after termination of this Agreement pursuant to Schedule 2.2, subsection (h),
the provisions of this Agreement otherwise applicable to the Manufactured Products that are the subject of such Firm Orders shall
survive termination of this Agreement.


 


ARTICLE
10

GENERAL PROVISIONS


 


10.1        Entire
Agreement; Amendment. This Agreement, together with the exhibits and schedules hereto, which are hereby incorporated herein,
represents the entire agreement and understanding between the Parties with respect to its subject matter and supersedes and terminates
any prior and/or contemporaneous discussions, representations or agreements, whether written or oral, of the Parties regarding
the subject matter hereto, and supersedes, as of the Effective Date, all prior and contemporaneous agreements and understandings
between the Parties with respect to the subject matter hereof (including for the Prior CDA). There are no covenants, promises,
agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as
are set forth in this Agreement. Amendments or changes to this Agreement shall be valid and binding only if in writing and signed
by duly authorized representatives of the Parties.


 


10.2        Force
Majeure. Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such
performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party.
Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes
reasonable efforts to remove the condition. For purposes of this Agreement, force majeure shall mean conditions beyond the control
of the Parties, including an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default
of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe,
and failure of plant or machinery (provided that such failure could not have been prevented by the exercise of skill, diligence,
and prudence that would be reasonably and ordinarily expected from a skilled and experienced person engaged in the same type of
undertaking under the same or similar circumstances). If a force majeure persists for more than ninety (90) days, then the Parties
shall discuss in good faith the modification of the Parties’ obligations under this Agreement in order to mitigate the delays
caused by such force majeure.


 




    	-18-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


10.3        Notices.
Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement,
and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such
Party in writing in accordance with this Section 10.3, and shall be deemed to have been given for all purposes (a) when received,
if hand-delivered or sent by confirmed facsimile or a reputable courier service, or (b) five (5) Business Days after mailing, if
mailed by first class certified or registered airmail, postage prepaid, return receipt requested.


 


		If to CCT:	Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics



Attn.: Chief Executive Officer


33 Technology Drive Warren, NJ 07059-5148


Fax: [****]


 


			With a copy to (which shall not constitute notice):



 


Proskauer Rose LLP


Eleven Times Square


New York, NY 10036


Attn: Robert A. Cantone, Esq.


Fax No.: (212) 969-2900


and


Celgene Corporation


86 Morris Avenue


Summit, NJ 07901


Attention: General Counsel


Fax: [****]


 


		If to Alliqua:	Alliqua, Inc.



2150 Cabot Boulevard West


Langhorne, Pennsylvania 19047


Attention: Chief Executive Officer


Fax No.: [****]


 


With a copy to (which shall
not constitute notice):


 


Lowenstein Sandler LLP


65 Livingston Avenue


Roseland, New Jersey 07068


Attention: Michael Lerner, Esq.


Fax No.: (973) 597-6395


 




    	-19-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


10.4         No
Strict Construction; Headings. This Agreement has been prepared jointly by the Parties and shall not be strictly construed
against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party
may be deemed to have authored the ambiguous provision. The headings of each Article and Section in this Agreement have been inserted
for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular
Article or Section. Except where the context otherwise requires, the use of any gender shall be applicable to all genders, and
the word “or” is used in the inclusive sense (and/or). The term “including” as used herein means including,
without limiting the generality of any description preceding such term.


 


10.5         Assignment.
Neither Party may assign this Agreement without the prior written consent of the other Party, such consent not to be unreasonably
withheld, conditioned or delayed; provided, however, that either Party may assign this Agreement without the consent of the other
Party, effective upon written notice to the other Party thereof, to (i) an Affiliate of such Party, provided that the Party hereunder
who assigns this Agreement agrees in writing to continue to be bound by and subject to the terms and conditions of this Agreement
and (ii) any Person who acquires all or substantially all of such Party’s assets or that is the surviving entity in a merger,
recapitalization, combination or other similar transaction with such assigning Party and who agrees in writing to be bound by and
subject to the terms and conditions of this Agreement. Further, CCT may assign without Alliqua’s consent its rights to payments
received under this Agreement. Any permitted assignment shall be binding on the successors of the assigning Party. Any attempted
or purported assignment in violation of this Section 10.5 shall be null and void.


 


10.6         Performance
by Affiliates. Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each
Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause
its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party’s
Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party
may proceed directly against such Party without any obligation to first proceed against such Party’s Affiliate.


 


10.7         Further
Actions. Each Party shall execute, acknowledge and deliver such further instruments, and to do all such other acts, as may
be necessary or appropriate in order to carry out the purposes and intent of this Agreement.


 


10.8         Severability.
If any provision of this Agreement is found by a court of competent jurisdiction to be unenforceable, then such provision shall
be construed, to the extent feasible, so as to render the provision enforceable, and if no feasible interpretation would save such
provision, it shall be severed from the remainder of this Agreement. The remainder of this Agreement shall remain in full force
and effect, unless the severed provision is essential and material to the rights or benefits received by either Party. In such
event, the Parties shall negotiate, in good faith, and substitute a valid and enforceable provision or agreement that most nearly
implements the Parties’ intent in entering into this Agreement.


 




    	-20-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


10.9         No
Waiver. No provision of this Agreement can be waived except by the express written consent of the Party waiving compliance.
Except as specifically provided for herein, the waiver from time to time by either Party of any of its rights or its failure to
exercise any remedy shall not operate or be construed as a continuing waiver of same or of any other of such Party’s rights
or remedies provided in this Agreement.


 


10.10       Independent
Contractors. For all purposes under this Agreement, Alliqua and CCT and their respective Affiliates are independent contractors
with respect to each other, and shall not be deemed to be an employee, agent, partner or legal representative of the other Party.
This Agreement does not grant any Party or its employees, consultants or agents any authority (express or implied) to do any of
the following without the prior express written consent of the other Party: create or assume any obligation; enter into any agreement;
make any representation or warranty; serve or accept legal process on behalf of the other Party; settle any claim by or against
the other Party; or bind or otherwise render the other liable in any way.


 


10.11       Governing
Law. This Agreement shall be governed by the laws of the state of New York, without regard to its choice of law provisions
that would require the application of the laws of a different jurisdiction. The Parties hereby irrevocably submit to the jurisdiction
of the state and federal courts sitting in the County and State of New York for the adjudication of disputes arising out of or
relating to this Agreement.


 


10.12       Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original but all of which together
shall constitute the same legal instrument. Facsimile or PDF execution and delivery of this Agreement by any Party shall constitute
a legal, valid and binding execution and delivery of this Agreement by such Party. The Parties to this document agree that a copy
of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature
may have been used. The Parties agree they will have no rights to challenge the use or authenticity of this document based solely
on the absence of an original signature.


 


[Signature page follows.]


 




    	-21-



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


IN WITNESS WHEREOF,
each of the Parties has caused this Agreement to be executed in duplicate, as of the Effective Date, by its duly authorized officer
or representative.


 


	ANTHROGENESIS CORPORATION	 	ALLIQUA, INC.
	 	 	 
	By: 	/s/ Perry Karsen	 	By: 	/s/ David Johnson
	Name: Perry Karsen 	 	Name:  David Johnson
	Title: Chief Executive Officer	 	Title:  Chief Executive Officer


 





[Signature Page to Supply Agreement]







 




    	 



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


SCHEDULE A


SPECIFICATIONS


 


[****]


 




    	 



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


SCHEDULE 2.2


 


(a)          Alliqua
shall submit to CCT as soon as practicable after the Effective Date, and in any event not later than the thirtieth (30th)
day after the date of this Agreement, and thereafter no later than the fifth (5th) Business Day of every month during the Term:


 


(i)          a
three (3) year rolling forecast (“Long Range Forecast”) organized by Manufactured Product stock keeping unit
and by quarterly periods, setting forth the quantities of each Manufactured Product that Alliqua expects to purchase from CCT during
the three (3) years commencing with the beginning of said month, and


 


(ii)         a
twelve (12)-month rolling forecast (“Forecast”) organized by Manufactured Product stock keeping unit and by
months, setting forth the quantities of each Manufactured Product that Alliqua expects to purchase from CCT during the twelve (12)-month
period commencing with the beginning of said month.


 


(b)          Alliqua
shall make all Forecasts and Long Range Forecasts in good faith given market and other information available to Alliqua. Each Forecast
shall constitute a binding commitment of Alliqua to purchase at least the percentages of Manufactured Products set forth below
pursuant to Firm Orders issued in accordance with Subsection (c) below, notwithstanding any change in the quantity of a Manufactured
Product specified in a subsequent Forecast. Except as provided in the preceding sentence, each Forecast shall be non-binding on
Alliqua. Each Long Range Forecast shall be non-binding on Alliqua. Alliqua shall be required to submit Firm Orders to purchase
at least that percentage of the quantity of each of the Manufactured Products specified in the Forecast as follows:


  


	Period of the Forecast	 	Percentage of the aggregate amount of

Manufactured Products that Alliqua is

required to submit Firm Orders for during

such period
	[****]	 	[****]
	[****]	 	[****]
	[****]	 	[****]


 




    	 



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


(c)          Alliqua
shall purchase Manufactured Products solely by Firm Orders for such Manufactured Products. For a given month, CCT will accept Firm
Orders for quantities of Manufactured Products, provided such Firm Orders in the aggregate do not exceed [****] of the quantity
set forth in the binding portion of the Forecast most recently submitted for such month; provided, however, that if, with respect
to any month, Alliqua orders any Manufactured Product in excess of [****] of the quantity set forth in the binding portion of the
Forecast most recently submitted for such month, CCT shall make commercially reasonable efforts to supply such excess up to [****]
of the quantity set forth in the binding portion of the Forecast most recently submitted for such month, but shall not be liable
for its failure to do so. Alliqua shall specify a delivery date in each Firm Order that is at least sixty (60) days after the date
on which the Firm Order is submitted to CCT. CCT shall, within five (5) Business Days after CCT receives each Firm Order submitted
in accordance with the preceding two sentences, accept in writing such Firm Order. Subject to any other term or condition of this
Agreement, Alliqua shall be obligated to purchase, and CCT shall be obligated to deliver by the required delivery date set forth
therein, such quantities of each Manufactured Product as are set forth in each Firm Order. If Alliqua requests changes to any Firm
Order previously submitted by Alliqua, including any increases or decreases in quantity of Manufactured Products, required delivery
date or form of Manufactured Product, CCT shall provide Alliqua a good faith estimate of the anticipated costs of complying with
such request. If Alliqua approves such estimated costs in writing, CCT shall use commercially reasonable efforts to comply with
such changes but shall not be liable for its failure to do so. In the event that CCT complies with any such request, Alliqua shall
reimburse CCT for its commercially reasonable, documented costs incurred in complying with such request. Notwithstanding anything
to the contrary in this subsection (c), during the first six months of Manufactured Product deliveries under this Agreement, CCT
shall have no obligation to deliver, nor to accept any portion of a Firm Order requiring it to deliver, more than the following
maximum number of Units (by size) per month as follows:





 


	 	Maximum Deliveries of Units, by Unit

Dimension
	[****]	[****]	[****]
	Each of the first three months of Manufactured Product deliveries under this Agreement	[****]	[****]	[****]
	Each of the fourth, fifth and sixth months of Manufactured Product deliveries under this Agreement	[****]	[****]	[****]


 


(d)          CCT
shall promptly notify Alliqua in writing if at any time CCT has reason to believe that CCT will not be able to (i) fill a Firm
Order for any Manufactured Product in accordance with the delivery schedule specified therein by Alliqua and pursuant to the terms
and conditions of this Agreement and the Quality Agreement, or (ii) supply Manufactured Products to Alliqua in satisfaction of
the most recent Forecast, which notice in either case shall provide Alliqua with information on the extent of the expected shortfall
of supply. Upon such notice of a supply shortfall, or in any event upon CCT's failure to satisfy, within the delivery time frame
specified by Alliqua, a portion of the Manufactured Products ordered by Alliqua in compliance with this Agreement and the Quality
Agreement, Alliqua and CCT will immediately meet and work together in good faith to identify an appropriate resolution to the supply
shortfall. Any agreed resolution to the supply shortfall will be set forth in a writing executed by both Parties. Compliance by
CCT with this subsection (d) shall not relieve CCT of any other obligation or liability under this Agreement, including any obligation
or liability under subsections (e) or (f) below.


 




    	 



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


(e)          If
CCT fails to deliver at least [****] of any Manufactured Products specified in a Firm Order conforming to the provisions of Subsection
(c) above by the required delivery date specified therein and in conformity with the applicable Specifications, Alliqua, at its
option, may:


 


(i)          cancel
all or any portion of such Firm Order with respect to such Manufactured Products, in which event Alliqua shall have no liability
with respect to the portion of such Firm Order so cancelled; or


 


(ii)         accept
late delivery of all or any portion of such Firm Order with respect to such Manufactured Product, in which event the Purchase Price
otherwise payable by Alliqua with respect to all Manufactured Products delivered late and accepted by Alliqua under such Firm Order
shall be reduced by [****].


 


(f)          If
CCT fails to deliver at least [****] of any Manufactured Products specified in a Firm Order conforming to the provisions of Subsection
(c) above by the required delivery date specified therein and in conformity with the applicable Specifications, CCT shall pay to
Alliqua any reasonable, documented external expenses incurred by Alliqua resulting from CCT’s breach of its obligation to
deliver the full quantity of any Manufactured Product specified in such Firm Order by the required delivery date specified therein.
Notwithstanding anything to the contrary in this Agreement, delivery by CCT of at least [****] of the quantity ordered will be
accepted by Alliqua in full satisfaction of CCT’s obligation to supply a Firm Order. Should delivered quantities of Manufactured
Product be below [****], CCT will use commercially reasonable efforts to accelerate the subsequent delivery of Manufactured Product,
if so requested by Alliqua. Alliqua will be invoiced for the actual quantities shipped, adjusted as provided in Subsection (e)(ii)
above. CCT will not be responsible for warehousing Manufactured Product for Alliqua. CCT will make available to Alliqua or Alliqua’s
designee, as the case may be, all Manufactured Products upon release.


 


(g)          The
remedies provided for in Subsections (e) and (f) above shall be the sole remedies of Alliqua with respect to any single failure
by CCT to deliver less than [****] of any Manufactured Product specified in a Firm Order conforming to the provisions of C 2.2(c)
by the required delivery date specified therein and in conformity with the applicable Specifications; and the remedy provided for
in Section 9.2(b) of the Agreement shall be the sole remedy of Alliqua with respect to the failure of CCT on at least [****] within
any [****] period to deliver at least [****] of any Manufactured Products specified in a Firm Order conforming to the provisions
of Schedule 2.2, subsection (c) by the required delivery date specified therein and in conformity with the applicable Specifications.


 


(h)          Notwithstanding
anything to the contrary in the Agreement, following termination of the Agreement pursuant to Sections 9.2(a) or (b), during the
twelve (12) month period commencing on the date notice of termination is given pursuant to either of such Sections (the “Termination
Supply Period”), Alliqua may submit Firm Orders for quantities of Manufactured Products in accordance with subsection
(c) above, except that the Firm Orders for any month during the last nine (9) months of the Termination Supply Period may not exceed
one hundred percent (100%) of the forecasted amount for such nine (9) months in the most recent Forecast provided by Alliqua to
CCT prior to such notice of termination.


 




    	 



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


SCHEDULE
2.5


ECM
PURCHASE PRICE


 


Purchase Price per unit of Manufactured Products, regardless
of dimensions thereof: $[****]


 


Maximum dimension of Manufactured Products: [****]


 




    	 



    	 



    

 


THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE
COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL
TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED
SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”.


 


SCHEDULE
4.1


BIOVANCE
PURCHASE PRICE


 


Purchase Price per unit of Manufactured Products, regardless
of dimensions thereof: $[****]


 


Maximum dimension of Manufactured Products: [****]